Substance interaction with the pulmonary resident cell membrane components leading
to pulmonary fibrosis
Lung fibrosis is a dysregulated or exaggerated tissue repair process resulting in
the thickening or scarring of lung tissue. It involves the presence of sustained or
repeated exposure to a stressor and intricate dynamics between several inflammatory
and immune response cells, and the microenvironment of the alveolar-capillary region
consisting of both immune and non-immune cells, and the lung interstitium. This AOP
is applicable to a broad group of stressors of diverse properties e.g. metal dusts,
pharmacological products, fibres, microorganisms, chemicals, including novel technology-enabled
stressors such as nanomaterials. This AOP is referred to as AOP 173 in the Collaborative
Adverse Outcome Pathway Wiki (AOP-Wiki).
Published on December 12, 2023
In series:OECD Series on Adverse Outcome Pathwaysview more titles